W
William H. Bradley
Researcher at Medical College of Wisconsin
Publications - 72
Citations - 4369
William H. Bradley is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Medicine & Olaparib. The author has an hindex of 16, co-authored 58 publications receiving 2212 citations. Previous affiliations of William H. Bradley include Western Connecticut Health Network & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung Gie Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Cara Mathews,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Paul DiSilvestro +20 more
TL;DR: The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression‐free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olAParib than with placebo.
Journal ArticleDOI
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martín,Bhavana Pothuri,Ignace Vergote,René dePont Christensen,Whitney Graybill,Mansoor Raza Mirza,C McCormick,Domenica Lorusso,Paul Hoskins,Gilles Freyer,Klaus Baumann,K. Jardon,Andrés Redondo,Richard G. Moore,Christof Vulsteke,Roisin E. O'Cearbhaill,Bente Lund,Floor J. Backes,Pilar Barretina-Ginesta,Ashley Haggerty,Maria J. Rubio-Pérez,Mark S. Shahin,Giorgia Mangili,William H. Bradley,Ilan Bruchim,Kaiming Sun,I Malinowska,Y. Li,Divya Gupta,Bradley J. Monk,Engot-Ov,Gog Investigators +31 more
TL;DR: Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival thanThose who received placebo, regardless of the presence or absence of homologous-recombination deficiency.
Journal ArticleDOI
Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung Gie Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Cara Mathews,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Paul DiSilvestro +20 more
TL;DR: Standard-of-care therapy for patients newly diagnosed with advanced ovarian cancer consists of frontline cytoreductive surgery and adjuvant platinum chemotherapy and approximately 70% of patients have a relapse within 3 years.
Journal ArticleDOI
A multi-institutional review of outcomes of endometrial stromal sarcoma
Charles A. Leath,Warner K. Huh,Johnny Hyde,David E. Cohn,Kimberly Resnick,Nicholas P. Taylor,Matthew A. Powell,David G. Mutch,William H. Bradley,Melissa A. Geller,Peter A. Argenta,Michael A. Gold +11 more
TL;DR: Low-grade and high-grade endometrial stromal sarcomas represent two distinct clinical entities and should be treated as such and the need for aggressive cytoreduction is suggested.
Journal ArticleDOI
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L. Coleman,Domenica Lorusso,Christine Gennigens,Antonio González-Martín,Leslie M Randall,David Cibula,Bente Lund,Linn Woelber,Sandro Pignata,Frederic Forget,Andrés Redondo,Signe Diness Vindeløv,Menghui Chen,Jeffrey R. Harris,Margaret Smith,Leonardo Viana Nicacio,Melinda S L Teng,Annouschka Laenen,Reshma A. Rangwala,Luis Manso,Mansoor Raza Mirza,Bradley J. Monk,Ignace Vergote,Francesco Raspagliesi,Bohuslav Melichar,Lydia Gaba Garcia,Amanda Jackson,Stephanie Henry,Zdenek Kral,Philipp Harter,Ugo De Giorgi,Maria Bjurberg,Michael Gold,David M. O'Malley,Brigitte Honhon,Christof Vulsteke,Eveline De Cuypere,Hannelore Denys,Jean-Francois Baurain,Claudio Zamagni,Meaghan Tenney,Mary Gordinier,William H. Bradley,Matthew Schlumbrecht,Nicola Spirtos,Nicole Concin,Sven Mahner,Giovanni Scambia,Charles Leath,Robin Farias-Eisner,Joshua Cohen,Carolyn Muller,Sumeet Bhatia +52 more
TL;DR: Tisotumab vedotin showed clinically meaningful and durable antitumour activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer as mentioned in this paper.